Dose-Escalation/Expansion Study of iMagic in Relapsed/Refractory Hematologic Malignancies
Dose-Escalation/Expansion Study of iMagic in Relapsed/Refractory Hematologic Malignancies
Not yet recruiting · NCT07802756 · Registry updated 2026-09-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Dose-Escalation/Expansion Study of iMagic in Relapsed/Refractory Hematologic Malignancies | Hemic and Lymphatic Diseases, Neoplasms by Site, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Not yet recruiting | Early phase 1 | 2026-09-08 | NCT07802756 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Suzhou Immunofoco Biotechnology Co., Ltd | 5 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College | Beijing | China | 6 |